Drug Trial Radar · NCT02607813
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Last checked: Nov 20, 2026Latest source record: Dec 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
142
Actual
Start
Jan 18, 2016
Primary completion
Feb 18, 2022
Study completion Feb 19, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
Conditions
- NSCLC
- Ovarian Cancer
- Melanoma
- Other Solid Tumors
Interventions
LXH254Drug
pan-RAF inhibitor
PDR001Drug
Biological: PDR001 anti-PD1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity.Time frame: From Cycle 1 Day 1 until 30 days for LXH254 single agent and 150 days for LXH254 in combination with PDR001 post study treatment (expected duration approximately 12 months)
- Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 single agent only)Time frame: 28 days
- Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 in combination with PDR001 only)Time frame: 56 days
Locations
18 sites in 10 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital MGH Cancer Center
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center SC - LXH254X2101
New York, New York
UT M.D Anderson Cancer Center SC - LXH254X2101
Houston, Texas
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Groningen, Netherlands
Medical Oncology, Erasmus MC
Rotterdam, Netherlands
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.